Importantly, VES-H8R8 demonstrated good cell uptake, retention and Pgp efflux inhibition in MDR cancer cells, which makes VES-H8R8 an ideal candidate for co-delivery with other chemotherapeutics, such as doxorubicin, for potential synergism. This evidence concerns the gene PGP and cancer.